Skip to main content
Erschienen in: International Journal of Hematology 3/2009

01.10.2009 | Case Report

Plasma cell leukemia producing monoclonal immunoglobulin E

verfasst von: Yuzuru Takemura, Masanobu Ikeda, Kahori Kobayashi, Yuji Nakazawa, Yuichi Mori, Toshimi Mitsuishi, Hiroki Ishigame, Fumiko Kameko, Kiyotaka Fujita, Ryo Ichinohasama

Erschienen in: International Journal of Hematology | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

A 78-year-old male with lumbar pain and dim consciousness presented the clinical pictures of plasma cell leukemia (PCL) producing a large amount of monoclonal immunoglobulin E (IgE)/kappa protein. Laboratory investigation demonstrated an elevated serum calcium level and renal dysfunction. Systemic bone X-ray survey disclosed only a solitary osteolytic lesion. Circulating plasma cells demonstrated CD19/CD56 and MPC-1/CD49e/CD45+/−, the latter indicating the immature phenotype of the tumor cells. Bone marrow was occupied with immature, atypical plasma cells, of which cytoplasms were positive for IgE by direct immunofluorescence analysis. Chromosomes revealed a translocation of (11;14)(q13;q32), which is concordant with cyclinD1-protein overexpression by immunohistochemistry. He was treated with dexamethasone and vincristine, which somewhat improved the laboratory findings. He died of tumor progression after 4-month admission. The clinical and biological characteristics of IgE-producing PCL, a very rare type of plasma cell dyscrasia, are discussed, reviewing the past literature.
Literatur
1.
Zurück zum Zitat Johansson SGO, Bennich H. Immunological studies of an atypical (myeloma) immunoglobulin. Immunology. 1967;13:381–94.PubMedPubMedCentral Johansson SGO, Bennich H. Immunological studies of an atypical (myeloma) immunoglobulin. Immunology. 1967;13:381–94.PubMedPubMedCentral
2.
Zurück zum Zitat Hayes MJ, Carey JL, Krauss JC, Hedstrom DL, Gulbranson RL, Keren DF. Low IgE monoclonal gammopathy level in serum highlights 20-yr survival in a case of IgE multiple myeloma. Eur J Haematol. 2007;78:353–7.CrossRefPubMed Hayes MJ, Carey JL, Krauss JC, Hedstrom DL, Gulbranson RL, Keren DF. Low IgE monoclonal gammopathy level in serum highlights 20-yr survival in a case of IgE multiple myeloma. Eur J Haematol. 2007;78:353–7.CrossRefPubMed
3.
Zurück zum Zitat Wozney JL, Ahmed F, Bayerl MG, Ehmann WC, Talamo G. Skin involvement in immunoglobulin E multiple myeloma. J Clin Oncol. 2009;27:637–8.CrossRefPubMed Wozney JL, Ahmed F, Bayerl MG, Ehmann WC, Talamo G. Skin involvement in immunoglobulin E multiple myeloma. J Clin Oncol. 2009;27:637–8.CrossRefPubMed
4.
Zurück zum Zitat Lloyd L, Klingberg SL, Kende M, Howell JF, Clague AE. A case of IgE multiple myeloma. Pathology. 2003;35:87–9.PubMed Lloyd L, Klingberg SL, Kende M, Howell JF, Clague AE. A case of IgE multiple myeloma. Pathology. 2003;35:87–9.PubMed
5.
Zurück zum Zitat Yamagata N, Shimazaki C, Goto H, Hirata T, Ashihara E, Oku N, et al. IgE plasma cell leukemia successfully treated with combination VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon-α. Am J Hematol. 1994;45:262–4.CrossRefPubMed Yamagata N, Shimazaki C, Goto H, Hirata T, Ashihara E, Oku N, et al. IgE plasma cell leukemia successfully treated with combination VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon-α. Am J Hematol. 1994;45:262–4.CrossRefPubMed
6.
Zurück zum Zitat Van Camp B, Durie BGM, Spier C, De Waele M, Van Riet I, Vela E, et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1, Leu-19). Blood. 1990;76:377–82.PubMed Van Camp B, Durie BGM, Spier C, De Waele M, Van Riet I, Vela E, et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1, Leu-19). Blood. 1990;76:377–82.PubMed
7.
Zurück zum Zitat Kraj M, Sokołowska U, Kopeć-Szlęzak J, Pogłód R, Kruk B, Woźniak J, et al. Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma. Leukemia Lymphoma. 2008;49:298–305.CrossRefPubMed Kraj M, Sokołowska U, Kopeć-Szlęzak J, Pogłód R, Kruk B, Woźniak J, et al. Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma. Leukemia Lymphoma. 2008;49:298–305.CrossRefPubMed
8.
Zurück zum Zitat Ridley RC, Xiao H, Hata H, Woodliff J, Epstein J, Sanderson RD. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood. 1993;81:767–74.PubMed Ridley RC, Xiao H, Hata H, Woodliff J, Epstein J, Sanderson RD. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood. 1993;81:767–74.PubMed
9.
Zurück zum Zitat Barker HF, Hamilton MS, Ball J, Drew M, Franklin IM. Expression of adhesion molecules LFA-3 and N-CAM on normal and malignant human plasma cells. Br J Haematol. 1992;81:331–5.CrossRefPubMed Barker HF, Hamilton MS, Ball J, Drew M, Franklin IM. Expression of adhesion molecules LFA-3 and N-CAM on normal and malignant human plasma cells. Br J Haematol. 1992;81:331–5.CrossRefPubMed
10.
Zurück zum Zitat Mahmoud MS, Ishikawa H, Fujii R, Kawano MM. Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6. Blood. 1998;92:3887–97.PubMed Mahmoud MS, Ishikawa H, Fujii R, Kawano MM. Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6. Blood. 1998;92:3887–97.PubMed
11.
Zurück zum Zitat Fujii R, Ishikawa H, Mahmoud MS, Asaoku H, Kawano MM. MPC-1−CD49e− immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas. Br J Haematol. 1999;105:131–40.CrossRefPubMed Fujii R, Ishikawa H, Mahmoud MS, Asaoku H, Kawano MM. MPC-1CD49e immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas. Br J Haematol. 1999;105:131–40.CrossRefPubMed
12.
Zurück zum Zitat Otsuyama K, Asaoku H, Kawano MM. An increase in MPC-1− and MPC-1−CD45+ immature myeloma cells in the progressive states of bone marrow plasmacytosis: the revised phenotypic classification of monoclonal marrow plasmacytosis (MOMP-2005). Int J Hematol. 2006;83:39–43.CrossRefPubMed Otsuyama K, Asaoku H, Kawano MM. An increase in MPC-1 and MPC-1CD45+ immature myeloma cells in the progressive states of bone marrow plasmacytosis: the revised phenotypic classification of monoclonal marrow plasmacytosis (MOMP-2005). Int J Hematol. 2006;83:39–43.CrossRefPubMed
13.
Zurück zum Zitat Avet-Loiseau H, Garand R, Lodé L, Harousseau JL, Bataille R. for the Intergroupe Francophone du Myélome. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood. 2003;101:1570–1.CrossRefPubMed Avet-Loiseau H, Garand R, Lodé L, Harousseau JL, Bataille R. for the Intergroupe Francophone du Myélome. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood. 2003;101:1570–1.CrossRefPubMed
14.
Zurück zum Zitat Gabrea A, Bergsagel PL, Chesi M, Shou Y, Kuehl WM. Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. Mol Cell. 1999;3:119–23.CrossRefPubMed Gabrea A, Bergsagel PL, Chesi M, Shou Y, Kuehl WM. Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. Mol Cell. 1999;3:119–23.CrossRefPubMed
15.
Zurück zum Zitat Pasqualetti P, Festuccia V, Collacciani A, Acitelli P, Casale R. Plasma cell leukemia. A report on 11 patients and review of the literature. Panminerva Med. 1996;38:179–84.PubMed Pasqualetti P, Festuccia V, Collacciani A, Acitelli P, Casale R. Plasma cell leukemia. A report on 11 patients and review of the literature. Panminerva Med. 1996;38:179–84.PubMed
16.
Zurück zum Zitat Macro M, André I, Comby E, Chèze S, Chapon F, Ballet JJ, et al. IgE multiple myeloma. Leukemia Lymphoma. 1999;32:597–603.CrossRefPubMed Macro M, André I, Comby E, Chèze S, Chapon F, Ballet JJ, et al. IgE multiple myeloma. Leukemia Lymphoma. 1999;32:597–603.CrossRefPubMed
17.
Zurück zum Zitat Ogawa M, Kochwa S, Smith C, Ishizaka K, McIntyre OR. Clinical aspects of IgE myeloma. N Engl J Med. 1969;281:1217–20.CrossRefPubMed Ogawa M, Kochwa S, Smith C, Ishizaka K, McIntyre OR. Clinical aspects of IgE myeloma. N Engl J Med. 1969;281:1217–20.CrossRefPubMed
18.
Zurück zum Zitat Yoshitake J, Hiramatsu S, Komatsubara Y, Matsubara T, Fujita T, Akutagawa H, et al. A case of IgE myeloma. Acta Haematol Jpn. 1976;39:862–75. Yoshitake J, Hiramatsu S, Komatsubara Y, Matsubara T, Fujita T, Akutagawa H, et al. A case of IgE myeloma. Acta Haematol Jpn. 1976;39:862–75.
19.
Zurück zum Zitat Vaerman JP. A new case of IgE myeloma (Des) ending with renal failure. J Clin Lab Immunol. 1979;2:343–8.PubMed Vaerman JP. A new case of IgE myeloma (Des) ending with renal failure. J Clin Lab Immunol. 1979;2:343–8.PubMed
21.
Zurück zum Zitat Gallango ML, Suinaga R, Ramírez M. IgE pyroglobulinemia in multiple myeloma. Clin Chim Acta. 1988;176:151–6.CrossRefPubMed Gallango ML, Suinaga R, Ramírez M. IgE pyroglobulinemia in multiple myeloma. Clin Chim Acta. 1988;176:151–6.CrossRefPubMed
22.
Zurück zum Zitat Kairemo KJA, Lindberg M, Prytz M. IgE myeloma: a case presentation and a review of the literature. Scand J Clin Lab Invest. 1999;59:451–6.CrossRefPubMed Kairemo KJA, Lindberg M, Prytz M. IgE myeloma: a case presentation and a review of the literature. Scand J Clin Lab Invest. 1999;59:451–6.CrossRefPubMed
23.
Zurück zum Zitat García-Sanz R, Orfão A, González M, Tabernero MD, Bladé J, Moro MJ, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93:1032–7.PubMed García-Sanz R, Orfão A, González M, Tabernero MD, Bladé J, Moro MJ, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93:1032–7.PubMed
24.
Zurück zum Zitat Pellat-Deceunynck C, Barillé S, Jego G, Puthier D, Robillard N, Pineau D, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia. 1998;12:1977–82.CrossRefPubMed Pellat-Deceunynck C, Barillé S, Jego G, Puthier D, Robillard N, Pineau D, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia. 1998;12:1977–82.CrossRefPubMed
25.
Zurück zum Zitat Cha CH, Park CJ, Huh JR, Chi HS, Suh CW, Kang YK. Significant better prognosis for patients with primary plasma cell leukemia than for patients with secondary plasma cell leukemia. Acta Haematol. 2007;118:178–82.CrossRefPubMed Cha CH, Park CJ, Huh JR, Chi HS, Suh CW, Kang YK. Significant better prognosis for patients with primary plasma cell leukemia than for patients with secondary plasma cell leukemia. Acta Haematol. 2007;118:178–82.CrossRefPubMed
26.
Zurück zum Zitat Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, et al. Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma. Blood. 2002;100:2195–202.PubMed Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, et al. Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma. Blood. 2002;100:2195–202.PubMed
27.
Zurück zum Zitat Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, et al. Osteoclasts enhance myeloma cell growth and survival via cell–cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood. 2004;104:2484–91.CrossRefPubMed Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, et al. Osteoclasts enhance myeloma cell growth and survival via cell–cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood. 2004;104:2484–91.CrossRefPubMed
28.
Zurück zum Zitat Hashimoto T, Abe M, Oshima T, Shibata H, Ozaki S, Inoue D, et al. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1α and MIP-1β correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol. 2004;125:38–41.CrossRefPubMed Hashimoto T, Abe M, Oshima T, Shibata H, Ozaki S, Inoue D, et al. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1α and MIP-1β correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol. 2004;125:38–41.CrossRefPubMed
Metadaten
Titel
Plasma cell leukemia producing monoclonal immunoglobulin E
verfasst von
Yuzuru Takemura
Masanobu Ikeda
Kahori Kobayashi
Yuji Nakazawa
Yuichi Mori
Toshimi Mitsuishi
Hiroki Ishigame
Fumiko Kameko
Kiyotaka Fujita
Ryo Ichinohasama
Publikationsdatum
01.10.2009
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 3/2009
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-009-0407-1

Weitere Artikel der Ausgabe 3/2009

International Journal of Hematology 3/2009 Zur Ausgabe

NSCLC: Progressionsfreies Überleben unter Osimertinib fast versiebenfacht

06.06.2024 ASCO 2024 Kongressbericht

Erste Ergebnisse der Phase-III-Studie LAURA etablieren Osimertinib als neuen Therapiestandard für Menschen mit nicht-resezierbarem, EGFR-mutiertem, nicht-kleinzelligem Lungenkarzinom im Stadium III, die nach definitiver Radiochemotherapie progressionsfrei sind. Auf der ASCO-Tagung wurden diese beeindruckenden Ergebnisse besprochen.

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gute molekulare Response, aber seltener ernste Nebenwirkungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.